

■ Natural Products

Total Synthesis of *Mycobacterium tuberculosis* Dideoxymycobactin-838 and Stereoisomers: Diverse CD1a-Restricted T Cells Display a Common Hierarchy of Lipopeptide Recognition

Janice M. H. Cheng^{+, [a, c, f, g]} Ligong Liu^{+, [b, h]} Daniel G. Pellicci,^[c, g] Scott J. J. Reddiex,^[c, g] Rachel N. Cotton,^[d] Tan-Yun Cheng,^[d] David C. Young,^[d] Ildiko Van Rhijn,^[d, e] D. Branch Moody,^[d] Jamie Rossjohn,^{*, [f, i, j]} David P. Fairlie,^{*, [b, h]} Dale I. Godfrey,^{*, [c, g]} and Spencer J. Williams^{*, [a, g]}

Abstract: *Mycobacterium tuberculosis* produces dideoxymycobactin-838 (DDM-838), a lipopeptide that potently activates T cells upon binding to the MHC-like antigen-presenting molecule CD1a. *M. tuberculosis* produces DDM-838 in only trace amounts and a previous solid-phase synthesis provided sub-milligram quantities. We describe a high-yielding solution-phase synthesis of DDM-838 that features a Mitsunobu substitution that avoids yield-limiting epimerization at lysine during esterification, and amidation conditions that prevent double-bond isomerization of the Z-C20:1 acyl

chain, and provides material with equivalent antigenicity to natural DDM-838. Isomers of DDM-838 that varied in stereochemistry at the central lysine and the C20:1 acyl chain were compared for their ability to be recognised by CD1a-restricted T cell receptors (TCRs). These TCRs, derived from unrelated human donors, exhibited a similar spectrum of reactivity towards the panel of DDM-838 isomers, highlighting the exquisite sensitivity of lipopeptide-reactive T cells for the natural DDM stereochemistry.

Introduction

Humans express four antigen-presenting proteins (CD1a, CD1b, CD1c and CD1d) belonging to the CD1 family, which

present lipid-based molecules to T cells via their T cell receptors (TCRs).^[1] CD1a differs from the other CD1 molecules owing to its constitutive, high-density expression on dendritic cells, termed Langerhans cells, in the skin and mucosa.^[2] Moreover,

[a] Dr. J. M. H. Cheng,⁺ Prof. S. J. Williams

School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, 3010 (Australia)
E-mail: sjwill@unimelb.edu.au

[b] Dr. L. Liu,⁺ Prof. D. P. Fairlie

Division of Chemistry and Structural Biology
Institute for Molecular Bioscience, The University of Queensland
Brisbane, Queensland 4072 (Australia)
E-mail: d.fairlie@imb.uq.edu.au

[c] Dr. J. M. H. Cheng,⁺ Dr. D. G. Pellicci, S. J. J. Reddiex, Prof. D. I. Godfrey

Department of Microbiology and Immunology
Peter Doherty Institute for Infection and Immunity
University of Melbourne, Parkville, Victoria 3010 (Australia)
E-mail: godfrey@unimelb.edu.au

[d] R. N. Cotton, Dr. T.-Y. Cheng, Dr. D. C. Young, Dr. I. Van Rhijn,

Prof. D. B. Moody
Division of Rheumatology, Immunology and Allergy
Brigham and Women's Hospital, Harvard Medical School
Boston, MA 02115 (USA)

[e] Dr. I. Van Rhijn

Department of Infectious Diseases and Immunology
School of Veterinary Medicine, University of Utrecht (The Netherlands)

[f] Dr. J. M. H. Cheng,⁺ Prof. J. Rossjohn

Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800 (Australia)
E-mail: jamie.rossjohn@monash.edu

[g] Dr. J. M. H. Cheng,⁺ Dr. D. G. Pellicci, S. J. J. Reddiex, Prof. D. I. Godfrey,

Prof. S. J. Williams
Australian Research Council Centre of Excellence for Advanced Molecular Imaging, University of Melbourne, Parkville
Victoria 3010 (Australia)

[h] Dr. L. Liu,⁺ Prof. D. P. Fairlie

Australian Research Council Centre of Excellence for Advanced Molecular Imaging, The University of Queensland, Brisbane
Queensland 4072 (Australia)

[i] Prof. J. Rossjohn

Australian Research Council Centre of Excellence for Advanced Molecular Imaging,
Monash University, Clayton
Victoria 3800 (Australia)

[j] Prof. J. Rossjohn

Institute of Infection and Immunity, Cardiff University School of Medicine
Cardiff CF14 4XN (UK)

[*] These authors contributed equally.

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under <http://dx.doi.org/10.1002/chem.201605287>

distinct from the other human CD1 molecules, CD1a possesses a cytoplasmic tail that lacks lysosomal targeting motifs. Thus, CD1a localizes predominantly at the cell surface where it can capture foreign or exogenous lipids. The only extensively characterized type of foreign lipidic molecule that activates CD1a-restricted T cells is a family of lipopeptides isolated from *Mycobacterium tuberculosis*, termed dideoxymycobactins (DDMs).^[3]

The initial discovery of the DDMs was achieved through bioassay-guided fractionation using a single T cell clone (CD8-2) obtained through stimulation and expansion with a chloroform/methanol *M. tuberculosis* extract.^[4] A three-dimensional X-ray structure of CD1a with a silylated, DDM-like lipopeptide showed the fatty acyl chain buried in the A' pocket of CD1a with the peptide protruding from the surface of CD1a, where it presumably contacts the TCR.^[5] The recent development of CD1a tetramers and dextramers that bind directly to polyclonal T cells in the ex vivo setting has allowed the detection and isolation of DDM-reactive T cell clones from small cohorts of tuberculosis patients.^[6] This suggests that CD1a–DDM reactive T cells occur in unrelated individuals and that CD1a–DDM tetramers may be useful reagents for the ex vivo diagnosis of *M. tuberculosis* infection. Furthermore, the existence of polyclonal T cells in small human cohorts raises the possibility that DDMs could be used to immunize or stimulate T cell responses in tuberculosis patients.^[6] However, the key obstacle to these lines of new medical technology development is the absence of an abundant supply of DDM.

DDMs are extremely potent, but comprise less than 10 parts per million of the cell wall mass of *M. tuberculosis*, a pathogen for which the laboratory cultivation is slow and cumbersome because it must be grown in biosafety level 3 conditions. Thus, isolation in high yield from natural sources remains impractical.^[3] The key challenge for chemical synthesis is that naturally occurring DDMs possess a complex depsipeptide backbone bearing a range of saturated and unsaturated fatty acyl groups linked through an amide to the ϵ -amino group of a lysine residue, and an unusual α -methylserine-derived angular methyl group. The structure of the most reactive compound, DDM-838 (1, Figure 1) was proposed through mass spectrometric and NMR analysis,^[3a] as well as the preparation of a range of possible stereoisomers and matching of their spectroscopic data and biological activity to the natural product,^[3b] and is consistent with the stereochemistry of the biosynthetically re-

lated mycobactins, iron-chelating hydroxamic acid siderophores.

A previous synthetic approach^[3b] to DDM-838 used solid-phase peptide chemistry to provide sufficient material to help clarify the structure of the natural product, yet the poor overall yield provided only sub-milligram quantities that are insufficient for in vivo studies. Prior work demonstrated that the correct stereochemistry at positions *a* and *c* (Figure 1), and the angular methyl group at position *a* are necessary for activating the DDM-reactive T cell clone CD8-2, and that natural DDMs lacking the unsaturation in the acyl chain are at least 10-fold less potent for T cell activation.^[3] In the present work we investigate solution-based peptide-coupling approaches for the preparation of milligram quantities of DDM-838. Through careful isolation of by-products produced in this process, we identify difficulties with the establishment of the key ester linkage that occurs with partial epimerization at lysine, a problem that may have occurred in the previous approach of Young and co-workers (unpublished). This and other problems were overcome by the development of a new route that creates the challenging ester linkage through a Mitsunobu coupling and allows the preparation of milligram quantities of DDM-838 (1). Through the isolation of stereochemical isomers of DDM-838 (2–4) we have explored structure–activity relationships in antigen recognition by the prototypical DDM-reactive T cell clone CD8-2, as well as new DDM-reactive clones, and demonstrate the importance of peptide and lipid stereochemistry for TCR recognition and T cell activation.

Results and Discussion

Total synthesis of DDM-838

Young and co-workers reported the synthesis of DDM-838 and analogues, emphasizing solid-phase approaches.^[3b] For the assembly of DDM-838 itself, a linear depsipeptide bearing the fatty acyl chain was assembled on Fmoc-Lys Sasrin (Fmoc=9-fluorenylmethoxycarbonyl) resin. Following release of the depsipeptide from the resin, the terminal lysine was cyclized to form the caprolactam moiety. After extensive HPLC purification, this approach yielded only trace quantities of DDM-838 (around 95 μ g or 2% overall yield), which we verified independently. As this synthesis was conducted on a solid phase, it is difficult to identify the yield-limiting steps. In a solution-phase approach, used for the synthesis of analogues that lacked the distinguishing α -methyl group, an ϵ -amino-protected dideoxymycobactinic acid was coupled to deoxycobactin, and the depsipeptide was deprotected prior to attaching the fatty acyl chain. This resulted in low yields for both attachment of the fatty acyl chain and for formation of the ester linkage. Moreover, unexpected doubling of signals in NMR spectra of advanced intermediates was attributed to the presence of rotational isomers, but could alternatively reflect the formation of undefined stereoisomers. With the above issues in mind, we initially sought to develop a solution-based synthesis of DDM-838 broadly inspired by this earlier study,^[3b] but with the intention to fully characterize all intermediates and identify yield-





Figure 1. DDM-838 (1) and three stereoisomers.

limiting steps in order to identify an improved synthetic approach.


The required building-block fragments deoxymycobactic acid **13**, deoxycobactin **16**, and *Z*-C20:1 fatty acid **20** were prepared by optimization of the previously described literature approaches.^[3b] Oxazoline acid **11** was prepared from α -methyl-serine **5**, by protection as the methyl ester **6**, which was con-

densed with 2-benzyloxysalicylic acid **8** using COMU to afford amide **9** (Scheme 1a).^[7] Cyclization to the oxazoline **10** proceeded smoothly with XtalFluor-M in CH₂Cl₂.^[8] Saponification of the ester of **10** with LiOH afforded the *O*-benzyl-protected acid **11**, which was coupled with NH₂-L-Lys(Boc)OMe using EDC-HCl/HOAt/DMAP (EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; HOAt = 1-hydroxy-7-azabenzotriazole; DMAP = 4-dimethylaminopyridine). Saponification of **12** afforded deoxymycobactic acid **13**. Next, deoxycobactin **16** was prepared by the coupling of (*R*)-3-hydroxybutyric acid **14** and L- α -amino- ϵ -caprolactam hydrochloride **15** in the presence of EDC-HCl/HOAt/DMAP (Scheme 1b).^[3b] Finally, the *Z*-C20:1 fatty acid **20** was synthesized using Ando's reagent,^[9] which enables a highly *Z*-selective Horner–Emmons–Wadsworth coupling. Treatment of octadecanol **17** with PCC (PCC = pyridinium chlorochromate) in CH₂Cl₂ afforded stearaldehyde **18**, which condensed with Ando's reagent^[9,10] in the presence of DBU/Nal (DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene) to afford a 9:1 *Z*:*E* ratio of alkenes **19** (use of the Still–Gennari reagent provided the alkenes in a 3:1 *Z*:*E* ratio) (Scheme 1c). These isomers could be separated by careful chromatography, prior to saponification to afford the acid **20**.

Coupling of deoxymycobactic acid **13** with deoxycobactin **16** was explored under a range of esterification conditions using assorted peptide coupling reagents. In general, the esterification reactions were slow and low yielding, and occurred with varying amounts of epimerization at lysine. The best results were achieved using DIC/HOAt (DIC = *N,N*'-diisopropylcarbodiimide) in the presence of 1.5 equivalents of DMAP, which afforded a 1:1 ratio of *S*-**21**/*R*-**21** (Scheme 2). Importantly, the *O*-benzyl protected epimeric intermediates **21** were separable by preparative thin-layer chromatography, but stereochemical assignment was not possible at this stage. Each isomer was individually carried through to the lipopeptide by



Scheme 1. Synthesis of deoxymycobactic acid **13**, deoxycobactin **16**, and *Z*-C20:1 fatty acid **20**.



Scheme 2. Preparation of DDM-838 (**1**) and stereoisomers **2–4**. Slow = higher polarity product; fast = lower polarity product. [a] Yield over 3 steps from (*S*- or (*R*)-**21**. [b] Analysis of ¹H NMR of crude mixture revealed the formation of 1.2:trifluoroacetamide byproduct at a ratio of 6:3:4, presumably derived from residual trifluoroacetate anion carried over from the previous step.

deprotection of benzyl and Boc groups (to give *S*- and *R*-**22**), then coupled with the *Z*-C20:1 acid **20** using EDC-HCl/HOAt/DMAP in the presence of *i*Pr₂NEt. Each product was formed as a mixture of *E* and *Z* isomers, which were separated by flash chromatography to afford four pure DDM isomers **1–4**, and in some cases small amounts of a contaminating trifluoroacetamide. The less polar isomer **21** afforded material whose spectral data matched the natural product DDM-838 (**1**). At this stage the stereochemistry of the central lysine was not known, but established later (*vide infra*).


The above work, and an alternative approach utilizing a different order of assembly that gave improved yields yet also suffered from similar problems (see Supporting Information for details), highlighted two key problems that likely contributed to the low yield of the prior solid- and solution-based syntheses of DDM-838.^[3b] The first is the difficulty of effecting the esterification of the 3-hydroxybutyramide, which occurred at best in only moderate yield and was complicated by epimerization at the central lysine. The difficulty of this coupling likely arises from the sterically congested nature of the linkage, between an α -branched acid, and a secondary alcohol. The propensity for epimerization at the central lysine during esterification of the 3-hydroxybutyramide group means that the stereochemistry at this position had not been unambiguously secured, although the biosynthetic relationship of DDM-838 to the mycobactins allows assumption of the *L*-configuration.^[11] The second problem was the unexpected isomerization of the unsaturated fatty acyl chain, and the sometimes contamination with a trifluoroacetamide by-product.

We initially focussed on solving the problem experienced with the unexpected formation of *E* and *Z* isomers upon acylation of *S*- and *R*-**22** with *Z*-C20:1 acid **20**, and the formation of the trifluoroacetamide by-product. By conversion of the trifluoroacetate salt of compound **22** to the free base, prior to acylation, we were able to avoid trifluoroacetamide formation. Treatment of a pure *Z*-C20:1-Lys model with *i*Pr₂NEt did not result in double bond isomerization, suggesting that isomerization was occurring to the activated acyl intermediate. Attempts to acylate the model amine (Bz-L-Lys-OMe) using DIC/HOAt/DMAP, without *i*Pr₂NEt or with pyridine, still led to double bond isomerization, suggesting that base-catalyzed isomerization is faster than acylation of lysine. Hocking has shown that double bond isomerization of *cis*-crotonoyl chloride during reaction with ammonia does not occur when ammonia is passed over the surface of an ethereal solution of the acid chloride.^[12] Inspired by this precedent, we examined pre-forming the activated ester by combining DIC and *Z*-C20:1 **20** in CH₂Cl₂, followed by addition of a CH₂Cl₂ solution of Bz-L-Lys-OMe, which afforded the *cis*-amide as the sole product.

To overcome the problem with epimerization at the central lysine, a Mitsunobu reaction was explored to form an ester bond and interchange the roles of the acid and alcohol to nucleophile and electrophile, respectively, thereby potentially alleviating the steric demands in forming this linkage. In related work, Miller and co-workers applied the Mitsunobu reaction in the synthesis of Mycobactins S and S2 through coupling of cobactin and mycobactin acid fragments in 49 and 50% yield, re-

spectively.^[13] In a recent article, Tsakos et al. reviewed a large number of challenging esterifications, and suggested that performing difficult esterification reactions on smaller fragments earlier in a sequence can often avoid yield-limiting side reactions by reducing the number of potentially interfering functional groups.^[14]

Based on these considerations we devised a second linear approach to DDM-838. Coupling of (*S*)-3-hydroxybutyric acid (*S*-**14**) (rather than (*R*)-**14**) to *L*- α -amino- ϵ -caprolactam **15** using EDC-HCl/HOAt/DMAP and afforded the deoxycobactin **23** (Scheme 3).^[3b] Mitsunobu coupling of **23** with Fmoc-L-



Scheme 3. Mitsunobu route to DDM-838 (**1**).

Lys(*Z*)-OH in the presence of Ph₃P/DIAD (DIAD = diisopropyl azodicarboxylate) afforded the ester **24** with the stereochemistry of 3-hydroxybutyrate inverted, and an elimination by-product **25** inseparable by flash chromatography. Although the yield of this reaction was modest, no epimerization at lysine was observed. Removal of the Fmoc group with piperidine allowed separation of the alkene **25** by chromatography and afforded pure amine **26** in 26% yield over two steps. Condensation of amine **26** and oxazoline acid **11** afforded the depsipeptide **27**. Global deprotection of depsipeptide **27** with H₂ over Pd/C gave enantiomerically pure amine *S*-**22**, which was isolated as a free base and then coupled with the *Z*-C20:1 acid **20**, this time using only DIC, and afforded DDM-838 **1** as a pure *Z* isomer in 49% yield over two steps. The spectral data were in agreement with the natural product. By this approach we unambiguously established the stereochemistry of DDM-838 (**1**) as *SSRS*, as well as the configuration of the three new stereoisomers (**2–4**) (Scheme 2 and Supporting Information).

Immunological investigation of CD1a-restricted T cell clones

We explored the ability of our synthetic compounds to mediate binding interactions between CD1a and TCRs using a series of immunological assays that measure either the biological potency of compounds in cellular assays (through the expression of activation marker CD69) or the mechanistic basis of TCR binding to CD1a-lipopeptide complexes (through tetramer

staining and flow cytometry). We studied several CD1a-restricted TCR⁺ clones including autoreactive clones that recognize CD1a alone, and those recognizing CD1a presenting foreign DDM and related antigens. Initially, we compared the biological activity of synthetic DDM-838 (**1**) prepared here, with natural DDM-838 isolated from *M. tuberculosis*, and material synthesized through the solid-phase route of Young and co-workers.^[3b] Titration of lipids into cultures of the native CD8-2 T cell clone with all three materials and quantification of IFN γ release by ELISA (enzyme-linked immunosorbent assay) provided




Figure 2. Synthetic and natural DDM-838 possess equivalent ability to activate the native CD8-2 T cell clone. Compound **1** prepared herein (solution phase); according to Young and co-workers (solid phase),^[3b] and isolated from *M. tuberculosis* H37Ra, were incubated with the human T cell clone CD8-2 and CD1a-expressing K562 myeloid cells^[15] over 24 h and IFN γ release measured by ELISA. DDM-838 isolated from *M. tuberculosis* contained 25% of the saturated analogue DDM-840,^[3a] which is less stimulatory than DDM-838. Error bars indicate standard deviation among triplicates. Data representative of three independent experiments. Controls at 0 nM DDM-838 are for experiments including T cells alone, K562 cells alone, and both cell lines.

dose-response curves for the two synthetic compounds that were essentially identical (Figure 2). The slightly lower potency of natural DDM can be explained by the presence of small amounts of naturally occurring variants in acyl chain length and saturation, which are known to be less potent than DDM-838.^[3] This result established the chemical identity of the synthetic compounds, and concordant activity with natural DDM-838.

The BK6 clone^[16] recognizes cellular CD1a when loaded with endogenous lipids and does not require DDM.^[17] Jurkat cells expressing the BK6 TCR were stained brightly by CD1a loaded with endogenous lipids (Endo, Figure 3a) (these endogenous lipids are derived from the mammalian HEK293 GnT1⁻ cells used for expression of CD1a monomers). By contrast, staining of Jurkat.BK6 cells was partially or completely inhibited by all four DDM analogues, suggesting that DDM lipids were loaded into CD1a and affected the TCR binding site. In contrast, Jurkat cells transfected with any of three TCRs derived from DDM-reactive T cell clones (CD8-2;^[4] and Clone 8 and Clone 15, isolated from two different subjects with latent tuberculosis infection) stained more brightly with CD1a tetramers loaded with synthetic DDM-838, compared to CD1a-Endo tetramers, indicating that synthetic lipopeptide enhances the interaction between CD1a and these TCRs. In comparing the hierarchy of CD8-2 staining, CD1a tetramers loaded with compound **2** (containing the *E*-C20:1 acyl lipid) stained less intensely than compound **1** (Figure 3b). Compound **3** (bearing the opposite stereochemistry at the central lysine residue compared to DDM-838), and compound **4** (with unnatural stereochemistry at




Figure 3. Reactivity of CD1a-restricted TCR⁺ Jurkat cell clones to DDM isomers. (a) Flow cytometry (left) of BK6, CD8-2, Clone-8, Clone-15 and M33 TCR-expressing cells labeled with CD1a-Endo tetramers or CD1a tetramers loaded with DDM-838 (*cis*-SSRS) **1**, DDM *trans*-SSRS **2**, DDM (*cis*-SRRS) **3** and DDM (*trans*-SRRS) **4**, or endogenous lipid antigen (Endo). Numbers in the bottom right corner indicate geometric mean fluorescence intensity (gMFI) of staining with CD1a-DDM or CD1a-Endo. (b) gMFI of each T cell line against Endo and DDM isomers **1–4**. Data are representative of three independent experiments.

lysine and the acyl lipid) showed minimal, if any staining of the DDM-838-reactive T cell clones. A negative control cell line expressing the MR1-restricted TCR, Jurkat.M33,^[18] provided only background staining levels with all of the CD1a tetramers, indicating that the interactions observed with CD1a-DDM tetramers were due to specific TCR interactions. These data indicate a role for peptide stereochemistry in T cell recognition, and further the highly similar patterns seen among three distinct TCRs suggests a conserved mechanism of DDM recognition.

To determine if synthetic DDMs could also activate cells, we next investigated if compounds 1–4 could cause TCR-transduced Jurkat cells to express an activation marker, CD69 (Figure 4). Titration of the DDM-reactive TCR⁺ CD8-2 cell line




Figure 4. Activation of Jurkat cells expressing BK6 and CD8-2 TCRs by C1R cells transduced to express CD1a, measured by expression of the activation marker CD69. BK6 and CD8-2 expressing cells were co-cultured overnight with CD1a-expressing C1R cells in the presence of DDM isomers 1–4 at varying concentrations (0.036, 0.12, 0.36, 1.2, 3.6 nM). For BK6 and CD8-2 expressing cells with a high TCR to GFP ratio, the level of CD69 expression was measured as mean fluorescence intensity (MFI). Data is representative of three independent experiments.

with compounds 1–4 resulted in a concentration-dependent increase in activation with the same pattern of potency as was observed in tetramer-based binding assays. CD1a-autoreactive BK6 cells showed no sign of activation by any of the compounds, and even showed a concentration-dependent reduction in activation. These data are consistent with lipopeptide loading into CD1a but reduced binding of CD1a-lipopeptide to the CD8-2 TCR for compounds 2–4. Titration of the DDM-reactive TCR⁺ Clone 8 and Clone 15 cell lines with 1–4 showed limited activation (data not shown).

Discussion

Although CD1a is broadly expressed on human Langerhans cells and myeloid dendritic cells, efforts to study foreign lipid-reactive CD1a-restricted T cells have been limited by the availability of the few known bacterial ligands. Although DDM-838 has been bound to CD1a and used in small-scale studies of tuberculosis patients,^[6] this depsipeptidolipid has only been available in trace quantities from either natural sources or the reported synthetic route. The present work has investigated several synthetic approaches to DDM-838; demonstrated a new approach that markedly improves yield; and provides insight into a conserved mechanism of DDM-recognition by CD1a-restricted T cells. The new method utilizes the Mitsunobu reaction to construct the challenging ester linkage and provides access to milligram quantities of this important mycobac-

terial antigen. Notably, unlike direct esterification methods that caused epimerization at the central lysine, this approach generates the ester linkage of the depsipeptide in a substitution reaction without epimerization, permitting an explicit assignment of the L-lysine stereochemistry of DDM-838.

The preparation of three diastereomers 2–4 of DDM-838 1 permitted investigation of structure–activity relationships for recognition by DDM-838 reactive CD1a-restricted TCRs, as well as the CD1a-autoreactive BK6 TCR. The BK6 TCR⁺ cell line is brightly stained by CD1a loaded with permissive self-lipids,^[17] but less brightly stained with CD1a tetramers treated with compounds 1–4. Structural studies have revealed that the BK6 TCR binds to the A' roof of CD1a, whereas non-permissive ligands such as sphingomyelin and sulfatide protrude from the A' cleft and disrupt the BK6 TCR-CD1a contact zone.^[17] An X-ray structure of a silylated mycobactin analogue revealed the alkyl chain inserted deep within the A' pocket of the antigen-binding groove, with the peptide folded over in the F' pocket and with both the caprolactam and salicyl moieties extending outward to the predicted plane of the TCR contact.^[5] This binary structure, as well as molecular modelling studies of CD1a-DDM-838 complexes,^[3] predict that the peptide moiety might block approach of the BK6 TCR to CD1a, based on the known docking mode of BK6 with CD1a.^[17] This prediction is supported by our results, which also provides evidence that all four DDM analogues bind to CD1a. Furthermore, Jurkat cells expressing the CD8-2, Clone 8 and Clone 15 TCRs fail to bind to CD1a tetramers loaded with self-lipids that are permissive to CD1a-BK6 TCR binding. This suggests an alternative TCR recognition mode compared to BK6 in which the peptide moiety likely protrudes from the groove to facilitate rather than block TCR binding.

Conclusions

Our data reveal a conserved spectrum of T cell recognition of the panel of DDM isomers by a set of three unrelated CD1a-DDM-reactive TCRs. The natural form, DDM-838 1 is the most potent, whereas compound 2, which varies in the lipid stereochemistry, maintained significant, albeit reduced, activity relative to 1. This result is reminiscent of the effect observed after saturating the acyl chain of DDM-838 to generate DDM-840,^[3a] demonstrating the importance of the *cis*- Δ^2 -unsaturation of DDM-838 for its potent antigenicity. The stereochemistry and location of this unsaturation (at C2) is unusual and is generated by mycobactin synthase N (MbtN).^[19] Although the biochemical function of the unsaturation is unknown, this work confirms its importance for antigen recognition.

The inversion of stereochemistry at the lysine of the depsipeptide backbone compromises the activity of lipopeptide and this was reflected in the low reactivity of the DDM-reactive TCRs to CD1a-compound 3 tetramers, similar to prior studies of DDM-838 varying at either the oxazoline or butyrate moieties (positions *a* and *c*, Figure 1).^[3b] The strong attenuation of TCR binding and T cell activation by compound 4, which is both epimerized at the central lysine and contains the *trans* acyl chain, reinforces these structure–activity relationships. Col-

lectively, these results reveal that the stereochemistry of the depsipeptide backbone is important for DDM-recognition by CD1a-restricted TCRs, and that variation in stereochemistry or saturation in the lipid chain leads to partial attenuation of reactivity. The recognition of DDM-838 **1** by three distinct T cell clones supports the development of these compounds to target the naturally occurring polyclonal T cells present in latent tuberculosis infected patients.^[6] The ability to synthesize larger quantities of DDM-838 by the solution-phase method described herein makes possible structural and functional studies of TCR recognition of CD1a-DDM-838 complexes, as well as in vivo studies that use DDM as a vaccine component or recall antigens for immunodiagnosis of tuberculosis.

Experimental Section

Expression and purification of CD1a

CD1a was expressed by recombinant methods in a mammalian expression system by cloning of constructs encoding CD1a and β_2 -microglobulin in a pHLsec vector^[20] as carboxyterminal fusions with the leucine zippers Jun (CD1a) and Fos (β_2 -microglobulin) and a "post-zipper" BirA-His₆ tag for CD1a. Fusion proteins were expressed by cotransfection of HEK293 GnT1⁻ cells with the plasmids pHLsec-CD1a-Jun-BirA-His₆ and pHLsec- β_2 m-Fos.^[17] Purification of CD1a- β_2 -microglobulin heterodimers was achieved by immobilized nickel affinity followed by size-exclusion chromatography.^[17]

Solubilization of DDM isomers

DDM SSRS Z-C20:1 **1**, DDM SSRS E-C20:1 **2**, DDM SRRS Z-C20:1 **3** and DDM SRRS E-C20:1 **4** were solubilized in a solution of 0.5% tyloxapol (Sigma) in Tris-buffered saline, pH 8.0 at 1 mg mL⁻¹. To ensure each lipopeptide was completely solubilized, 12 rounds of sonication (1 h, water bath temperature 25–45 °C), vortex (10 sec) and freezing at –20 °C (20 mins) were performed until the mixture was a homogenous suspension.

Production of CD1a-restricted Jurkat 76 cell lines

CD1a-restricted BK6, CD8-2, Clone 8, Clone 15 and control MR1-restricted M33.64^[23] Jurkat 76 cells were generated as described^[24] using retroviral transduction whereby green fluorescent protein and an antibody to CD3 ϵ (*anti*-CD3 ϵ ; UCHT1; BD Biosciences) signified successful transduction. Parental Jurkat 76 cells lack endogenous TCR α -chains and β -chains,^[22] and therefore TCR specificity is conferred by the transgene. These have recently been tested and confirmed to be free of *Mycoplasma*.

Loading of CD1 a, production of CD1 a tetramers and staining of Jurkat 76 cells with CD1 a tetramers

Soluble mammalian CD1a samples were enzymatically biotinylated with BirA biotin ligase as previously described.^[21] Biotinylated CD1a was loaded overnight with each DDM isomer at a molar ratio of 1:6. DDM-loaded biotinylated CD1a monomers were tetramerized with streptavidin-phycoerythrin (BD Biosciences). 3×10^4 CD1a-restricted BK6, CD8-2, Clone 8, Clone 15 and control MR1-restricted M33.64 Jurkat 76 cells, generated as described above were incubated with *anti*-CD3 ϵ (UCHT1; BD Biosciences) and CD1a-DDM tetramers for 25 mins and CD1a tetramer staining intensity determined on the CD3e⁺ Jurkat 76 cells, and were analyzed with an

LSR Fortessa (BD Biosciences). Data were processed with FlowJo software (TreeStar).

Assay of activation of the human BK6 and CD8-2 Jurkat 76 cell lines

CD1a-restricted BK6 and CD8-2 Jurkat 76 cells were generated as described above. CD1a-expressing C1R cells were generated as previously described.^[17] 3.33×10^3 CD1a-expressing C1R cells were co-cultured overnight with 2×10^4 Jurkat cells (BK6 or CD8-2) and DDM isomers **1–4** at varying concentrations (0.036, 0.12, 0.36, 1.2, 3.6 nM). The cells were collected by centrifugation, the supernatant was removed and the cells were then stained with *anti*-CD3 ϵ (BV421, UCHT1, BD Biosciences), *anti*-CD69 (PE, FN50, BD Biosciences), *anti*-CD19 (APC/Cy7, SJ25C1, BD Biosciences) and 7-AAD (Sigma Aldrich). Activation of CD3⁺, GFP high (top 50%) BK6 and CD8-2 Jurkat 76 cells were assessed by upregulation of CD69. Cells were analyzed with an LSR Fortessa (BD Biosciences) and data were processed with FlowJo software (TreeStar).

Activation of human T cell clone CD8-2 by three sources of DDM-838 (1)

CD1a-expressing K562 myeloid cells have been described previously and are routinely tested by flow cytometry to confirm surface CD1a expression.^[15] DDM-838 from solid-phase synthesis was provided by Dr David Young using the reported method.^[3b] Natural DDM was purified from *M. tuberculosis* H37Ra as described previously^[3b] and characterized by electrospray ionization mass spectrometry to be a mixture of DDM-838 (75%) and DDM-840 (25%). The concentrations of DDM-838 in natural DDM and of solution-phase DDM-838 were determined by UV spectroscopy absorbance at 306 nm, normalized to absorbance of 80 μ m solid-phase DDM-838. 5×10^4 CD8-2 T cells were incubated with 2.5×10^4 CD1a-expressing K562 cells and serial dilutions of DDM-838 in 150 μ L T cell media for up to 24 hr at 37 °C. Secreted IFN γ in the undiluted cell culture media was quantified by standard sandwich ELISA using human IFN γ antibody clones 2G2 (Thermo-Fisher), biotin-conjugated B133.5 (Thermo-Fisher) and streptavidin horse radish peroxidase (BD Pharmingen). Absorbance was measured at 405 nm using a VersaMax plate reader (Molecular Devices) and SoftMaxPro software. IFN γ concentrations were extrapolated from a standard curve in GraphPad Prism 6.

Acknowledgements

This work was supported by the Australian Research Council (DP130102763, DP160100597, FT130100103, CE140100011 and LE110100106). DGP is supported by an NHMRC ECF fellowship (1054431); D.P.F. and D.I.G. are supported by NHMRC Senior Principal Research Fellowships (1027369, 1020770); J.R. is supported by an ARC Laureate Fellowship; D.B.M. is supported by the Bill and Melinda Gates Foundation Vaccine Accelerator Award and NIH (R01 AI1049313 and U19 AI111224).

Keywords: antigens · immunology · natural products · peptidolipids · T cells

[1] D. I. Godfrey, A. P. Uldrich, J. McCluskey, J. Rossjohn, D. B. Moody, *Nat. Immunol.* **2015**, *16*, 1114.

- [2] a) L. Meunier, L. Vian, C. Lagoueyte, T. Lavabre-Bertrand, C. Duperray, J. Meynadier, J. P. Cano, *Cytometry* **1996**, *26*, 260; b) R. E. Hunger, P. A. Sieling, M. T. Ochoa, M. Sugaya, A. E. Burdick, T. H. Rea, P. J. Brennan, J. T. Belisle, A. Blauvelt, S. A. Porcelli, R. L. Modlin, *J. Clin. Invest.* **2004**, *113*, 701.
- [3] a) D. B. Moody, D. C. Young, T. Y. Cheng, J. P. Rosat, C. Roura-Mir, P. B. O'Connor, D. M. Zajonc, A. Walz, M. J. Miller, S. B. Levery, I. A. Wilson, C. E. Costello, M. B. Brenner, *Science* **2004**, *303*, 527; b) D. C. Young, A. Kasmar, G. Moraski, T. Y. Cheng, A. J. Walz, J. Hu, Y. Xu, G. W. Endres, A. Uzieblo, D. Zajonc, C. E. Costello, M. J. Miller, D. B. Moody, *J. Biol. Chem.* **2009**, *284*, 25087.
- [4] J. P. Rosat, E. P. Grant, E. M. Beckman, C. C. Dascher, P. A. Sieling, D. Fredérique, R. L. Modlin, S. A. Porcelli, S. T. Furlong, M. B. Brenner, *J. Immunol.* **1999**, *162*, 366.
- [5] D. M. Zajonc, M. D. Crispin, T. A. Bowden, D. C. Young, T. Y. Cheng, J. Hu, C. E. Costello, P. M. Rudd, R. A. Dwek, M. J. Miller, M. B. Brenner, D. B. Moody, I. A. Wilson, *Immunity* **2005**, *22*, 209.
- [6] A. G. Kasmar, I. Van Rhijn, K. G. Magalhaes, D. C. Young, T. Y. Cheng, M. T. Turner, A. Schiefner, R. C. Kalathur, I. A. Wilson, M. Bhati, S. Gras, R. W. Birkinshaw, L. L. Tan, J. Rossjohn, J. Shires, S. Jakobsen, J. D. Altman, D. B. Moody, *J. Immunol.* **2013**, *191*, 4499.
- [7] A. El-Faham, R. S. Funosas, R. Prohens, F. Albericio, *Chem. Eur. J.* **2009**, *15*, 9404.
- [8] a) M.-F. Pouliot, L. Angers, J.-D. Hamel, J.-F. Paquin, *Tetrahedron Lett.* **2012**, *53*, 4121; b) M.-F. Pouliot, L. Angers, J.-D. Hamel, J.-F. Paquin, *Org. Biomol. Chem.* **2012**, *10*, 988.
- [9] K. Ando, *J. Org. Chem.* **1997**, *62*, 1934.
- [10] K. Ando, T. Oishi, M. Hiram, H. Ohno, T. Ibuka, *J. Org. Chem.* **2000**, *65*, 4745.
- [11] C. A. Madigan, T. Y. Cheng, E. Layre, D. C. Young, M. J. McConnell, C. A. Debono, J. P. Murry, J. R. Wei, C. E. Barry 3rd, G. M. Rodriguez, I. Matsunaga, E. J. Rubin, D. B. Moody, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 1257.
- [12] M. B. Hocking, *Can. J. Chem.* **1968**, *46*, 466.
- [13] a) P. J. Maurer, M. J. Miller, *J. Am. Chem. Soc.* **1983**, *105*, 240; b) J. Hu, M. J. Miller, *J. Am. Chem. Soc.* **1997**, *119*, 3462.
- [14] M. Tsakos, E. S. Schaffert, L. L. Clement, N. L. Villadsen, T. B. Poulsen, *Nat. Prod. Rep.* **2015**, *32*, 605.
- [15] A. de Jong, V. Pena-Cruz, T. Y. Cheng, R. A. Clark, I. Van Rhijn, D. B. Moody, *Nat. Immunol.* **2010**, *11*, 1102.
- [16] S. Porcelli, M. B. Brenner, J. L. Greenstein, S. P. Balk, C. Terhorst, P. A. Bleicher, *Nature* **1989**, *341*, 447.
- [17] R. W. Birkinshaw, D. G. Pellicci, T. Y. Cheng, A. N. Keller, M. Sandoval-Romero, S. Gras, A. de Jong, A. P. Uldrich, D. B. Moody, D. I. Godfrey, J. Rossjohn, *Nat. Immunol.* **2015**, *16*, 258.
- [18] R. Reantragoon, L. Kjer-Nielsen, O. Patel, Z. Chen, P. T. Illing, M. Bhati, L. Kostenko, M. Bharadwaj, B. Meehan, T. H. Hansen, D. I. Godfrey, J. Rossjohn, J. McCluskey, *J. Exp. Med.* **2012**, *209*, 761.
- [19] C. A. Madigan, A. J. Martinot, J. R. Wei, A. Madduri, T. Y. Cheng, D. C. Young, E. Layre, J. P. Murry, E. J. Rubin, D. B. Moody, *PLoS Pathog.* **2015**, *11*, e1004792.
- [20] A. R. Aricescu, W. Lu, E. Y. Jones, *Acta Crystallogr. D Biol. Crystallogr.* **2006**, *62*, 1243.
- [21] C. A. O'Callaghan, M. F. Byford, J. R. Wyer, B. E. Willcox, B. K. Jakobsen, A. J. McMichael, J. I. Bell, *Anal. Biochem.* **1999**, *266*, 9.
- [22] a) E. A. Shima, M. M. Le Beau, T. W. McKeithan, J. Minowada, L. C. Showe, T. W. Mak, M. D. Minden, J. D. Rowley, M. O. Diaz, *Proc. Natl. Acad. Sci. U. S. A.* **1986**, *83*, 3439; b) M. H. M. Heemskerck, M. Hoogeboom, R. A. de Paus, M. G. D. Kester, M. A. W. G. van der Hoorn, E. Goulmy, R. Willemze, J. H. F. Falkenburg, *Blood* **2003**, *102*, 3530.
- [23] R. Reantragoon, A. J. Corbett, I. G. Sakala, N. A. Gherardin, J. B. Furness, Z. Chen, S. B. G. Eckle, A. P. Uldrich, R. W. Birkinshaw, O. Patel, L. Kostenko, B. Meehan, K. Kedzierska, L. Liu, D. P. Fairlie, T. H. Hansen, D. I. Godfrey, J. Rossjohn, J. McCluskey, L. Kjer-Nielsen, *J. Exp. Med.* **2013**, *210*, 2305.
- [24] A. P. Uldrich, J. Le Nours, D. G. Pellicci, N. A. Gherardin, K. G. McPherson, R. T. Lim, O. Patel, T. Beddoe, S. Gras, J. Rossjohn, D. I. Godfrey, *Nat. Immunol.* **2013**, *14*, 1137.

Manuscript received: November 13, 2016

Accepted Article published: December 7, 2016

Final Article published: January 18, 2017